Moneycontrol
    Moneycontrol PRO

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct

    • Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher

    • Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher

    • Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher

    • Ipca Laboratories Q2 PAT seen up 7.3% YoY to Rs 292.6 cr: Prabhudas Lilladher

    • Ipca Lab Q1 PAT may dip 53.5% YoY to Rs 207.6 cr: ICICI Direct

    • IPCA Q4 PAT seen up 126.5% YoY to Rs. 194.8 cr: Sharekhan

    • IPCA Labs: API capacity constraint almost out of the way

    • Ipca Labs Q3 PAT seen up 4.9% YoY to Rs. 207.2 cr: Yash Securities

    • Ipca Labs Q2 PAT seen up 34% YoY to Rs. 160.2 cr: Emkay

    • IPCA Laboratories Q1 PAT seen up 34.1% YoY to Rs. 87.9 cr: Prabhudas Lilladher

    • IPCA Laboratories Q4 PAT seen up 106.1% YoY to Rs. 105.8 cr: Prabhudas Lilladher

    • IPCA Labs Q3 PAT seen up 1.5% YoY to Rs. 107.2 cr: ICICI Direct

    • IPCA Labs Q2 PAT may dip 7.3% YoY to Rs. 89.4 cr: ICICI Direct

    • IPCA Laboratories Q4 PAT seen up 209.3% YoY to Rs. 83.8 cr: Edelweiss

    • IPCA Q1 PAT seen up 153% to Rs 95.4 cr: Edelweiss

    • Buy IPCA; it is well valued for long-term investors: Angel

    • Pharma companies revenues to rise 12% in Q3: Anand Rathi

    • See India biz grow 15%, exports to rise 25% in H2: Ipca

      Ipca Labs hopes to continue doing very well in H2FY14 especially in its India formulation business, says ED AK Jain. It is awating USFDA approvals for Indore SEZ which, the company feels will boost its business going forward.

    • May revise guidance upwards post Q2: Ipca Labs

      AK Jain, ED, Ipca Labs told CNBC-TV18 that the start of the earnings for the company is very good and down the line maybe after Q2 it may revise the guidance.

    • Pharma cos likely to post 21% EBITDA growth in Q4: MOST

      Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

    • Improvement in gross margins likely to continue: Ipca Labs

      Last week, Ipca Laboratories reported net profit of Rs 87.89 crore for the quarter ending December 31, 2012 on the back of strong sales across domestic and international markets. AK Jain, ED, Ipca Laboratories told CNBC-TV18 that the margins are going to remain in the regions of around 32 percent plus.

    • Good performance likely from pharma in Q3: Nirmal Bang

      Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).

    • See pharma sector's Q3 topline to grow 22%: Motilal Oswal

      Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

    • See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

      Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347